1. Introduction {#sec1-cancers-12-01505}
===============

In the last decade, the monitoring of molecular minimal residual disease (MRD) has become the gold standard in routine clinical practice both in pediatric and adult acute lymphoblastic leukemia (ALL) to improve risk stratification and define therapeutic strategies \[[@B1-cancers-12-01505],[@B2-cancers-12-01505],[@B3-cancers-12-01505],[@B4-cancers-12-01505],[@B5-cancers-12-01505]\]. Indeed, the evaluation of MRD during induction and maintenance chemotherapy, or after hematopoietic stem cell transplantation (HSCT), is nowadays considered the strongest predictive factor for ALL prognosis \[[@B6-cancers-12-01505],[@B7-cancers-12-01505]\]. The availability of MRD data relies on a standardized, time-consuming, and intense procedure applying PCR amplification to detect the most frequent immunoglobulin/T-cell receptor (Ig/TCR) gene rearrangements and leukemic fusion transcripts at diagnosis \[[@B8-cancers-12-01505],[@B9-cancers-12-01505],[@B10-cancers-12-01505],[@B11-cancers-12-01505]\]. However, in about 5-10% of cases, the use of this method fails to identify suitable markers for MRD evaluation \[[@B12-cancers-12-01505]\], precluding patients' allocation in the most adequate risk class which is crucial to define the most suitable therapy and to promptly prevent relapse. This failure can be attributed to the PCR technique limitation concerning both the design and resolution of the assay. As a matter of fact, the large number of possible combinations of variable, diversity, and joining (V-D-J) gene segments is faced by PCR with a restricted number of primer combinations that can be used to affordably assess clonal rearrangement identification due to diagnostic DNA availability, time to assay set-up, and costs. Therefore, a PCR-based panel designed for clonality assessment at disease presentation is ineffective in identifying rare rearrangements and in solving oligoclonality/low clonality issues.

New high-throughput technologies have become available and are being explored in order to overcome the limits of the conventional and standardized MRD assessment \[[@B13-cancers-12-01505]\]. A next-generation sequencing (NGS) approach, similarly based on rearrangement amplification by PCR, has been described to identify clonal markers at diagnosis \[[@B14-cancers-12-01505],[@B15-cancers-12-01505],[@B16-cancers-12-01505]\] and to monitor MRD in lymphoid malignancies \[[@B17-cancers-12-01505],[@B18-cancers-12-01505],[@B19-cancers-12-01505],[@B20-cancers-12-01505],[@B21-cancers-12-01505]\]. All in all, NGS-based Ig/TCR marker screening greatly improved MRD monitoring, being less time consuming, and highlighted the polyclonal false-positive scenario. An alternative to amplicon-based NGS for Ig/TCR marker screening is a capture enrichment NGS procedure based on the hybridization of probes selecting all the known V, D, and J regions irrespective of their recombination status \[[@B22-cancers-12-01505]\]. The capture method also allows for the inclusion of highly complex (i.e., TCRA) or preferentially amplified Ig/TCR regions, which can hinder multiplex PCR technique \[[@B14-cancers-12-01505]\]. Therefore, this approach can potentially identify all the possible rearrangements also offering, by a single test and using the same amount of specimen, the possibility to include other probes recognizing leukemia-related DNA regions such as chromosomal translocation partners \[[@B22-cancers-12-01505]\] or genes with prognostic significance in hematologic malignancies \[[@B23-cancers-12-01505]\]. Recently, many molecular alterations have been suggested as possible candidates for predicting ALL outcome \[[@B24-cancers-12-01505]\], or defining precise features such as Philadelphia chromosome-like leukemia \[[@B25-cancers-12-01505]\].

In this context, we developed a custom capture-based NGS approach for Ig/TCR clonal marker identification at disease onset, also including the analysis of the mutational status of 25 genes relevant in diagnostic workup and prognosis of ALL \[[@B24-cancers-12-01505]\]. We aimed to demonstrate its value in identifying common and uncommon Ig/TCR rearrangements as well as gene mutational status and its prospective applicability to better define risk class.

2. Results {#sec2-cancers-12-01505}
==========

2.1. Validation of the Capture-Based NGS Panel {#sec2dot1-cancers-12-01505}
----------------------------------------------

We applied a newly designed capture-based NGS assay (panel v1, see Materials and Methods) to 10 previously characterized diagnostic samples. By comparing both Ig/TCR annotation and complementarity-determining region 3 (CDR3) sequence, we identified 51 rearrangements already found by standard PCR-based clonality assessment and Sanger sequencing. This novel approach also detected 24 additional clonal rearrangements involving the following loci: IGH (*n* = 4), IGK (*n* = 2), IGL (*n* = 1), TCRB (*n* = 4), TCRG (*n* = 2), and TCRA and TCRD (*n* = 11). These clonal rearrangements were mainly characterized by uncommon V-D-J combinations, low clonal representation, and oligoclonality that could not be solved by the conventional homo-heteroduplex clonality assessment ([Table 1](#cancers-12-01505-t001){ref-type="table"}).

The validation of these NGS-recognized rearrangements using standard methods required further efforts compared to routine procedures---11 uncommon V-D-J combinations were amplified by rearrangement-specific primers designed based on NGS data (*n* = 5 in TCRA, *n* = 1 in TCRD, and *n* = 5 in αδ (TCRA+D) loci) and sequenced by Sanger method; three low-represented clonalities (*n* = 1 IGH, *n* = 1 TCRB, and *n* = 1 IGL) that were missed by low sensitive regular PCR were finally revealed by standard method only after re-amplification of faint heteroduplex PCR products and Sanger sequencing; 10 oligoclonal rearrangements (*n* = 2 IGK, *n* = 3 IGH, *n* = 3 TCRB, and *n* = 2 TCRG) were amplified and recognized within the typical, overlapped Sanger electropherograms. Notably, the analysis of NGS data derived from human umbilical vein endothelial cells (HUVECs) and mesenchymal cord blood cells samples did not identify any rearrangement in Ig/TCR genes, testifying that no false rearrangements were produced during library preparation, sequence generation, or data analysis.

2.2. Retrospective Application of the Capture-Based NGS Panel to MRD-Unknown ALL Patients {#sec2dot2-cancers-12-01505}
-----------------------------------------------------------------------------------------

The capture-based NGS assay (panel v1) was then applied to a retrospective group of 23 ALL patients (13 B-lineage ALL and 10 T-lineage ALL) enrolled into the Northern Italy Leukemia Group (NILG)-ALL 09/00 clinical trial for whom it had been impossible to isolate clonal rearrangements or to obtain a sensitive patient-specific molecular probe (MRD-unknown). These patients could not have benefited from an MRD driven treatment and were treated according to the clinical risk score. In this cohort, the capture-based NGS allowed for the identification of at least 1 rearrangement in 20 out of 23 patients (87%), recognizing overall 92 clonal rearrangements (IGH (*n* = 30), IGK (*n* = 6), TCRB (*n* = 6), TCRG (*n* = 32), and TCRA and TCRD (*n* = 18)) detailed in [Table 2](#cancers-12-01505-t002){ref-type="table"}.

In all 13 adult B-lineage ALL cases, we recognized by NGS at least one D-J or V-D-J clonal rearrangement, identifying a total of 72 rearrangements. On the contrary, our approach identified D-J or V-D-J clonal rearrangements in 7 out of 10 adult T-lineage ALL cases. Among the complete cohort of MRD unknown patients, we found 21 out of 92 rearrangements at level \<5% that were not subjected to validation due to the 5% detection limit of standard procedure. Conversely, 69 rearrangements defined by NGS with a level ≥5% underwent the validation process by the conventional method. Among these 69 cases, 53 were successfully amplified and Sanger sequenced using implemented standard PCR methods based on the updated EuroMRD guidelines or specific PCR appropriately designed for uncommon rearrangements based on NGS sequences. For 16 out of 69 rearrangements, we could not confirm the NGS sequences by conventional Sanger sequencing because it does not allow for the discrimination of clones sharing the same V-J genes but with different junctional regions. Confirmation was not possible for two rearrangements identified in one sample due to diagnostic DNA exhaustion.

2.3. Prospective Application of the Capture-Based NGS Panel and Patient-Specific Probe Design {#sec2dot3-cancers-12-01505}
---------------------------------------------------------------------------------------------

The prospective application of our capture-based NGS panel allowed for the identification of at least one rearrangement in 10 out of 12 patients (83%), with a total of 40 clonal rearrangements identified, located in the following loci: IGH (*n* = 4), IGK (*n* = 6), IGL (*n* = 3), TCRB (*n* = 5), TCRG (*n* = 14), and TCRA and TCRD (*n* = 8) ([Table 3](#cancers-12-01505-t003){ref-type="table"}).

In all the three adult B-lineage ALL studied cases, we recognized D-J or V-D-J clonal rearrangements by NGS capture approach, identifying overall 18 rearrangements, including seven clonal rearrangements already isolated by conventional method, but not adequate to patient-specific probe generation. Among the nine remaining adult T-lineage cases, we identified D-J or V-D-J clonal rearrangements in seven patients. Overall, the newly-identified rearrangements were again mainly characterized by an uncommon V-D-J combination. In addition, an IGK rearrangement, routinely tested exclusively in B-lineage ALL, was recognized as clonal in a T-lymphoblastic lymphoma (T-LL) case, and one TCRG clonal rearrangement was not previously identified because it was a very low represented clone (below the sensitivity of the homo/heteroduplex assay). Interestingly, the standard heteroduplex assessment failed to recognize two newly identified clonal rearrangements (*n* = 1 IGH and *n* = 1 IGK), despite their high clone abundance and the monoclonal feature. Additionally, two newly identified IGH bi-clonal rearrangements were not tested by the standard procedure because the paucity of the diagnostic bone marrow material did not allow for the performance of the complete conventional PCR panel. In the high-throughput approach, 600 ng of DNA was sufficient to perform the experiment and study the entire Ig/TCR region. In one of the two cases still lacking a clonal marker, the blasts percentage in the diagnostic bone marrow sample was around 5% (BG_39541).

On the basis of sequences provided by NGS, we were able to design allele-specific oligonucleotide (ASO)-qPCR assays for the MRD assessment. In cases for whom enough material was available (9 out of 10), we validated the assays on standard curve dilutions of diagnostic specimen in normal buffycoat. All the Ig/TCR rearrangements, including uncommon V-D-J combinations, proved useful as MRD markers. In detail, in five cases, we obtained at least one patient-specific assay with the required sensitivity of 10^−5^ and quantitative range of 10^−4^, confirming that the found rearrangements represented major leukemia clones missed by the conventional approach at diagnosis. For two patients, assays reached the sensitivity of 10^−4^ and the quantitative range of 10^−3^, while in the other two cases, the sensitivity was less than 10^−4^. Although low-sensitive assays are not useful to asses MRD negativity, they can identify MRD-positive patients, allowing appropriate medical intervention to avoid hematologic relapse. MRD assessment based on developed assays allows for the prompt allocation of one MRD-positive patient to stem cell transplant.

2.4. Gene Variant Analysis by NGS Approach {#sec2dot4-cancers-12-01505}
------------------------------------------

The single nucleotide variant (SNV) and insertion/deletion (indel) analysis of the genes of interest allowed for the identification of 51 gene variants in 18 out of 19 (94.7%) analyzed patients (5 B- and 14 T-lineage), involving the following genes: CREB Binding Protein (*CREBBP*), Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit (*EZH2*), F-Box And WD Repeat Domain Containing 7 (*FBXW7*), Fms Related Receptor Tyrosine Kinase 3 (*FLT3*), Isocitrate Dehydrogenase (NADP(+)) 2 (*IDH2*), IKAROS Family Zinc Finger 1 (*IKZF1*), Janus Kinase 1 (*JAK1*), Janus Kinase 2 (*JAK2*), Janus Kinase 3 (*JAK3*), KRAS Proto-Oncogene, GTPase (*KRAS*), Notch Receptor 1 (*NOTCH1*), NRAS Proto-Oncogene, GTPase (*NRAS*), Paired Box 5 (*PAX5*), Phosphatase And Tensin Homolog (*PTEN*), SH2B Adaptor Protein 3 (*SH2B3*), Tet Methylcytosine Dioxygenase 2 (*TET2*), and Tumor Protein P53 (*TP53*). The variant allele fraction (VAF) of the identified variants ranged from 5% to 79% ([Table 4](#cancers-12-01505-t004){ref-type="table"}).

In all the B-ALL patients (BG_41985, BG_11584, BG_41182, BG_42309, and BG_5038), we identified a single variant involving one single gene (*FLT3*, *TP53, JAK2*, *CREBBP*, and *PAX5*, respectively), while only one T-ALL patient (BG_21292) presented a single gene involved. Interestingly, this T-ALL case harbored two mutations in the involved *PTEN* gene ([Figure 1](#cancers-12-01505-f001){ref-type="fig"}).

In the remaining 13 T-lineage-derived samples, we identified the presence of gene variants involving at least two genes and we observed a statistically significant correlation between T-lineage and the increase of mutations number per patient (*p* = 0.005). Concordantly with the literature, variants in *NOTCH1* were present in 7 out of 14 (50%) T-lineage patients \[[@B26-cancers-12-01505],[@B27-cancers-12-01505]\] of the studied cohort and were associated with gene variants in *NRAS*, *TP53* or *JAK1*, and *JAK3*. No matter the co-occurrence with *NOTCH1* variants, *NRAS* mutations were located in the nucleotide-binding domain region of the protein. Furthermore, we observed a co-occurrence of variants in *JAK1*, *JAK3*, and *NOTCH1* genes in three different patients. In these cases, the *JAK1* gene harbored variants in the pseudokinase domain, while *JAK3* alterations, co-mutated with *JAK1* and *NOTCH1*, involved the JH1 kinase domain (p.L857P and p.D846N) or the linker region between the SH2 domain and the pseudokinase domain (p.M511I). This latter variant was previously described in T-cell malignancies as an activating amino acid change \[[@B28-cancers-12-01505]\]. The *NOTCH1* variants associated with *JAK1* and *JAK3* mutations were located in the juxtamembrane heterodimerization (HD) N-terminal domain, but in one of these cases (BG_40129) we identified two additional variants of *NOTCH1* (p.P2514H and p.A2463PfsTer14) involving the domains PEST (a peptide sequence rich in proline (P), glutamic acid (E), serine (S), and threonine (T)) and TAD (transcriptional activation domain), respectively.

A statistical analysis performed on the co-occurrence of gene variants, although a limited number of patients were molecularly profiled, demonstrated a statistically significant association between *JAK1* and *JAK3* (*p* = 0.004) and *JAK1* and *NOTCH1* (*p* = 0.04). Moreover, in the T-LL studied samples, we identified the association of *IDH2* mutations and the presence of variants involving *SH2B3* (*p* = 0.09), while the co-occurrence of *FLT3* and *IKZF1* variants was observed in two out of three T-ALL cases. We did not observe any association between gene variants and specific Ig/TCR rearrangements. Of note, several variants (ranging from two to five) were identified in three patients in whom no Ig/TCR rearrangements were recognized.

3. Discussion {#sec3-cancers-12-01505}
=============

In this work, we developed and validated a novel capture-based NGS panel useful for Ig/TCR clonal marker screening and gene variant identification at diagnosis of ALL.

Although the identification process of leukemia-associated clonal Ig/TCR has been developed and ruled during the last 20 years within European collaborative networks (EuroClonality and EuroMRD, part of ESHLO foundation), this procedure remains laborious, time-consuming, and, in some cases, ineffective. Therefore, MRD stratification using the gold standard ASO-qPCR approach is nowadays feasible in about 95% of cases \[[@B12-cancers-12-01505]\]. NGS technology has been demonstrated to be a powerful tool for the identification of clonal rearrangements at disease presentation, resulting in being less laborious and easier to perform than standard techniques \[[@B14-cancers-12-01505],[@B15-cancers-12-01505],[@B16-cancers-12-01505]\]. Indeed, NGS proved faster compared to multistep standard workflow, allowing an efficient patient-specific probe design for timely MRD assessment, based on NGS-derived sequences.

Our capture-based NGS assay identified all clonal rearrangements previously found by standard PCR and allowed the additional identification of clonal markers that are difficult to detect by multiplex PCR \[[@B14-cancers-12-01505]\]. It also provided [Supplementary Information](#app1-cancers-12-01505){ref-type="app"} about bi-clonalities, oligoclonalities, and uncommon rearrangements. This latter aspect is particularly important in patients in whom no Ig/TCR clonalities can be identified by standard procedure. In our clinical study, which started in the year 2000, this MRD-unknown cohort represented 16% of the enrolled patients \[[@B5-cancers-12-01505]\]. These patients could not have been followed during the treatment with an MRD patient-specific probe, allowing a treatment based only on clinical features that often proved not completely adequate to define the relapse risk of the patient. Therefore, we verified this new power of the assay on patients prospectively enrolled into the active trial in which the standard method failed. In this cohort for 9 out of 10 (90%) patients, a useful MRD assay has been designed on clonal sequences provided by capture-based NGS assay, thus allowing a prospective risk-class assignment (50%) or an MRD persistence identification. Moreover, NGS offers an important improvement in terms of increased sensitivity, resulting in the possibility to identify at diagnosis minor leukemia clones that could eventually be responsible for unexpected relapse. Indeed, the MRD monitoring by ASO-qPCR requires the choice of one or two clonal rearrangements for follow-up measurements \[[@B8-cancers-12-01505],[@B29-cancers-12-01505]\], usually selected for better sensitivity and reflecting, in most cases, the abundance of the leukemic clone among the cell population. Therefore, the ASO-qPCR approach necessarily leads to losing track of minor subclones that might resist therapy and be responsible for disease resistance or reappearance \[[@B8-cancers-12-01505]\]. Given this and considering our results, it could be desirable to explore all the possible rearrangements, including the uncommon ones not included into the standard PCR panel or amplicon-based NGS panel recently published \[[@B14-cancers-12-01505]\]. Nowadays, some but not all lineage-specific rearrangements are investigated either in T- and B-lineage ALL with current methods. Indeed, it could be suitable to test all possible rearrangements in any ALL in order to avoid the missing of unexpected clonal markers.

A desirable approach to MRD assessment is also NGS-based. Some companies are offering a full MRD evaluation by receiving diagnostic and follow-up samples. The development of a standardized amplicon-based, open access method is still ongoing within collaborative groups \[[@B21-cancers-12-01505]\] in which assay sensitivity and proper quantitation are the main issues. Upon resolving these issues, one point of weakness still should be faced, namely, the search of only a few, highly represented clones identified at diagnosis. This latter point would not be a problem for a capture-based method in which all the rearrangements are entirely studied in each experiment.

The capture-based NGS approach also proved useful for saving the diagnostic material collected at disease onset. Indeed, the amount of 1 μg of genomic DNA required for the complete NGS panel for clonal marker screening, including the study of rare rearrangements and gene profiling, is much lower than the amount of DNA needed for the amplicon-based techniques and the genetic profiling performed separately. This consideration is pivotal, especially from the perspective in which nowadays the MRD evaluation is still performed by ASO-qPCR, using serial dilutions of the diagnostic specimen, with MRD quantification being expressed as logarithmic reduction compared to the leukemia burden at disease onset. On the other hand, promising, newly described techniques such as amplicon NGS or droplet digital PCR (ddPCR), aiming to achieve absolute quantification of the residual leukemia level, are still under investigation and are not yet standardized \[[@B30-cancers-12-01505]\]. Additionally, the saving of diagnostic material is essential in hypocellular specimens or when *punctio sicca* occurs and follow-up sample analysis is required for a long period of time.

In our work, all B-ALL MRD-unknown patients, tested retrospectively as well prospectively, showed at least one clonal rearrangement, while all patients still lacking a molecular marker in our cohort belonged to the T-lineage group. For two of these patients, we can speculate that the tested diagnostic sample was not adequate for the appropriate analysis. In fact, in one case (BG_4005), the blasts percent content in the diagnostic sample was not available and we cannot exclude that the specimen was not leukemia-representative. Likewise, the blasts percentage in the bone marrow diagnostic sample for patient BG_39541 was around 5%, not sufficient to the proper leukemia diagnosis according to the World Health Organization criteria. Even then, we can suppose that the available diagnostic specimen was not correctly evaluable. However, the results thus far obtained could suggest the definition of a small subgroup of very immature T-ALL in which Ig/TCR rearrangements had not yet occurred, although further analysis is required to speculate the maturation stage of leukemic lymphoblasts and to exclude technical limitations. Nevertheless, our NGS approach allowed us to identify very small leukemia clones, representing less than 1% of the global leukemia population; however, lacking a spike-in control to normalize clonal rearrangement size compared to physiological rearrangements in normal lymphocytes, we could not exclude a technical bias. Notably, the not-yet reported use as negative controls of HUVECs and mesenchymal cells revealed no generation of artificial rearrangements during library generation or bioinformatic data interpretation. In any case, it is important to note that the group of prospectively analyzed MRD-unknown patients is characterized by a strong prevalence of T-lineage cases, while globally the ratio between B- and T-ALL cases is unbalanced towards B-lineage occurrence.

The demanding process to obtain a mutational analysis of several genes that are prognostically significant \[[@B23-cancers-12-01505]\] or defining leukemia cases with specific features (Philadelphia-like ALL) \[[@B25-cancers-12-01505]\] prompted us to include a number of relevant genes into the capture design. This resulted in the identification of several mutations in the studied ALL cases. In particular, all the B-ALL cases harbored single gene variants involving *CREBBP*, *FLT3*, *JAK2*, *PAX5*, and *TP53.* On the contrary, in all the T-ALL-derived samples, we observed the presence of at least two gene variants, with a statistically significant increase of the mutations number in T-lineage patients compared to B-ALL cases. On the basis of the data thus far obtained, we can conclude that for T-ALL patients the inclusion of mutational status analysis of leukemia-associated genes could improve not only the general knowledge about leukemogenesis, but it could have important consequences in clinical practice. Indeed, we identified gene variants in three out of five T-ALL patients in which no informative Ig/TCR rearrangements were recognized. Two of these variants were druggable mutations (*IDH2* p.R140Q) that could be considered for therapeutic intervention.

Some limitations must be acknowledged. Our approach increases the complexity and the costs to identify clonal markers. Capture-based technology is not yet standardized and it should be externally validated before being routinely applied in clinical practice. Finally, this was a single center study in which only a limited number of patients were evaluated. A clinical multicenter validation was undertaken within the Euro-clonality NGS consortium \[[@B22-cancers-12-01505]\].

4. Materials and Methods {#sec4-cancers-12-01505}
========================

4.1. Capture-Based NGS Panel Design {#sec4dot1-cancers-12-01505}
-----------------------------------

Two different capture-based NGS panels were designed using gene coordinates mapped on GRCh38/hg38 gene assembly, targeting coding V, D, and J genes in the Ig/TCR loci for the identification of D-J and V-D-J rearrangements (panel v1, 180 kb) and both Ig/TCR related regions, as well as a selected group of genes of interest listed in [Table S1](#app1-cancers-12-01505){ref-type="app"} (panel v2, 350 kb). No differences were detected between the two panels when applied to the same diagnostic sample (see [Table S2](#app1-cancers-12-01505){ref-type="app"}, patient BG_5038) and no reduction in our ability to identify V-D-J rearrangements was observed. The mean of targeted aligned reads was 149,256 reads (min 228, max 276,500) for panel v1 and 2,391,017 reads (min 1893, max 4,392,496) for panel v2. The minimum analyzed (i.e., rearranged) sequences per sample should have been at least 1000.

4.2. Clinical Samples {#sec4dot2-cancers-12-01505}
---------------------

Panel v1 was applied for the identification of clonal rearrangements on diagnostic bone marrow material of 10 adult ALL patients (6 B- and 4 T-lineage, median age 33 years), including 2 human umbilical vein endothelial cell (HUVEC) samples and 2 mesenchymal cord blood cell samples as negative controls for Ig/TCR rearrangements. These patients have been formerly studied for clonality assessment following the conventional EuroMRD guidelines \[[@B9-cancers-12-01505],[@B10-cancers-12-01505]\], within the NILG-ALL 09/00 clinical trial ([ClinicalTrials.gov](ClinicalTrials.gov) identifier: NCT00358072) \[[@B5-cancers-12-01505]\]. The same capture-based NGS approach for clonality assessment was applied on 23 adult ALL patients (13 B- and 10 T-lineage, median age 43 years) enrolled into the NILG-ALL 09/00 trial, in which the identification of a suitable MRD molecular marker with standard procedure failed (MRD-unknown). The NGS panel v2 was validated on diagnostic bone marrow samples of 7 adult ALL patients formerly evaluated for Ig/TCR rearrangements and analyzed for *TP53* mutational status by an independent NGS protocol (6 out of 7) \[[@B23-cancers-12-01505]\]. The same panel was prospectively used on 12 newly diagnosed ALL patients (3 B-, 7 T-lineage, and 2 T-lymphoblastic lymphoma (T-LL); median age 40 years) missing suitable MRD assays by standard approach. Patients' clinical and biological characteristics are reported in [Tables S2 and S3](#app1-cancers-12-01505){ref-type="app"}. Since no oligoclonalities emerged from the analysis of capture-NGS performed on highly diluted diagnostic samples in normal polyclonal mononuclear cells (serial dilutions according to EuroMRD guidelines), we did not perform any specific tests to evaluate oligoclonalities in normal, polyclonal lymphocytes.

4.3. DNA Extraction, Library Preparation, and Sequencing {#sec4dot3-cancers-12-01505}
--------------------------------------------------------

Genomic DNA was isolated by Gentra Puregene Cell Kit (Qiagen, Hilden, Germany) or Maxwell 16 Cell LEV DNA Purification Kit (Promega, Madison, WI, USA) from bone marrow mononuclear cells obtained by Ficoll gradient (Cedarlane Laboratories Ltd., Burlington, ON, Canada). For library preparation, we fragmented 600 ng--1 µg of genomic DNA to an average size of 600 bp by Covaris S220 Focused-Ultrasonicator (Covaris, Woburn, MA, USA) or Kapa enzymes (Kapa Biosystems, Wilmington, MA, USA). Libraries in the pre-hybridization steps were prepared with the KAPA HyperPlus Kit (Kapa Biosystems, Wilmington, MA, USA) and were then hybridized to our custom-designed EZ SeqCap gene panel (Roche NimbleGen, Madison, WI, USA). The pool of enriched libraries was sequenced on a MiSeq platform, using 300 bp paired-end reads (v3 chemistry, Illumina, San Diego, CA, USA).

4.4. NGS Data Analysis and Statistical Analysis {#sec4dot4-cancers-12-01505}
-----------------------------------------------

Bioinformatics data were processed separately. The identification of Ig/TCR rearrangements was performed through the open-source application Vidjil ([www.vidjil.org](www.vidjil.org)) \[[@B31-cancers-12-01505],[@B32-cancers-12-01505]\]. Uncommon V-D-J combinations were considered according to previously published literature \[[@B33-cancers-12-01505],[@B34-cancers-12-01505],[@B35-cancers-12-01505],[@B36-cancers-12-01505]\]. Low clonal representation was stated when a V-(D)-J annotation with unique CDR3 region sequence was present with a clone size between 5% and 10% in the locus. Oligoclonality was defined when the same V-(D)-J annotation was present with 3 or more different CDR3 regions each having a clonal size ≥ 5%. The variant calling for gene alterations was performed by MiSeq Reporter Software, and visualization of results was achieved by Illumina VariantStudio Data Analysis Software (Illumina, San Diego, CA, USA) and the Integrative Genomics Viewer tool (<http://software.broadinstitute.org/software/igv/>) \[[@B37-cancers-12-01505],[@B38-cancers-12-01505]\]. For gene variant analysis, we considered only variants with a read depth of at least 100 reads and VAF of 5%. Associations between different gene variants and between gene variants and other characteristics were assessed using the Fisher exact test for categorical variables and Wilcoxon rank-sum test for continuous variables. Two-sided *p*-values \<0.1 were considered significant. Statistical analysis was performed with R software (version 3.6.2).

4.5. Clonality Assessment Validation {#sec4dot5-cancers-12-01505}
------------------------------------

In all samples, we determined the Ig/TCR gene rearrangements at diagnosis by PCR, homo-heteroduplex clonality assay, and Sanger sequencing according to BIOMED protocols \[[@B9-cancers-12-01505],[@B10-cancers-12-01505]\]. The finger-print CDR3 regions of V-D-J gene rearrangements were detailed through the IMGT V-Quest web application ([www.IMGT.org](www.IMGT.org)). Additional rearrangements found by NGS were validated by BIOMED-1/2 primers, if available, or by custom-made PCR primers. The design of the latter was based on the Ig/TCR annotation derived from NGS sequences studied by IMGT; V-, D-, and J-specific primers were designed by Primer Express Software v2.0 (Applied Biosystems, Foster City, CA, USA) following BIOMED-1/2 recommendations. After PCR amplification, we performed homo-heteroduplex clonality assay and Sanger sequencing. In case of weak PCR product in heteroduplex analysis \[[@B10-cancers-12-01505]\], we applied band elution and a second amplification before Sanger sequencing.

5. Conclusions {#sec5-cancers-12-01505}
==============

In conclusion, our results indicated that the prospective application of NGS remarkably simplified the assessment of clonality in adult ALL, providing additional information about the mutational status of some ALL-related genes, with it now being the new standard to identify the most informative Ig and TCR markers for the prospective evaluation of MRD.

Despite the long and extraordinarily successful history of Ig/TCR-based MRD evaluation for childhood \[[@B1-cancers-12-01505],[@B2-cancers-12-01505],[@B39-cancers-12-01505],[@B40-cancers-12-01505]\] and adult ALL patients \[[@B3-cancers-12-01505],[@B4-cancers-12-01505],[@B5-cancers-12-01505],[@B41-cancers-12-01505]\], we have to keep in mind that Ig/TCR are clonality markers and MRD evaluation reflects the leukemia chemo-sensitivity. No insight into leukemia development or targeted therapy can be drawn. This approach was developed in times in which the main information on ALL gene mutations was the broad gene involvement with low frequency and there was no technical support for the study of such a large number of genes. Nowadays, many new technologies have been developed that offer the possibility to analyze huge genome sections.

Our NGS approach including Ig/TCR rearrangements as well as mutations in an increasable number of genes could be a valid bridge toward a targeted MRD evaluation, allowing the accumulation of a solid, comparative, and prospective experience.

The following are available online at <https://www.mdpi.com/2072-6694/12/6/1505/s1>, Table S1: List of genes included in the enhanced version of the capture-NGS panel (panel v2), Table S2: Clinical and biological characteristics of adult ALL patients evaluated for the validation of the capture-NGS panel v1, Table S3: Clinical and biological characteristics of adult ALL patients lacking an informative Ig/TCR molecular marker for MRD evaluation (MRD-unknown).
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cancers-12-01505-t001_Table 1

###### 

Immunoglobulin/T-cell receptor (Ig/TCR) rearrangements identified by next-generation sequencing (NGS) in the cohort of adult acute lymphoblastic leukemia (ALL) patients enrolled into the Northern Italy Leukemia Group (NILG)-ALL 09/00 clinical trial, formerly evaluated for clonality assessment. These rearrangements have been (Yes) or not (No) previously detailed by standard clonality assessment and Sanger sequencing following the conventional EuroMRD guidelines.

  Patient ID   ALL Lineage     Locus   V Gene           del V   *n*            del D   D Gene         del D   *n*           del J   J Gene                       Known   Rearrangement Feature
  ------------ --------------- ------- ---------------- ------- -------------- ------- -------------- ------- ------------- ------- ---------------------------- ------- ----------------------------
  BG_371       B               IGH     IGHV3-9\*01      −2      15             −2      IGHD6-19\*01   −4      7             0       IGHJ3\*02                    Yes     /
  TRD+         TRDV2\*02       −4      10               −28     TRDD3\*01      NA      NA             NA      NA            Yes     /                                    
  TRG          TRGV2\*01       0       20               NA      NA             NA      NA             −3      TRGJ1\*01     Yes     /                                    
  TRG          TRGV3\*02       −4      15               NA      NA             NA      NA             −6      TRGJ1\*02     Yes     /                                    
  BG_4502      T               TRB     TRBV11-2\*03     0       9              −3      TRBD2\*01      −5      1             −4      TRBJ2-1\*01                  Yes     /
  TRB          TRBV14\*02      −3      4                −1      TRBD2\*01      NA      NA             NA      TRBJ2-6\*01   Yes     /                                    
  TRD          TRDV1\*01       0       15               0       TRDD3\*01      −2      1              −3      TRDJ1\*01     Yes     /                                    
  TRG          TRGV3\*02       −1      10               NA      NA             NA      NA             −4      TRGJ1\*02     Yes     /                                    
  TRG          TRGV9\*01       −1      13               NA      NA             NA      NA             −6      TRGJ1\*02     Yes     /                                    
  BG_5038      B               IGH     IGHV3-49\*02     −15     8              −2      IGHD2-8\*01    0       2             −2      IGHJ6\*02                    Yes     /
  IGK          IGKV1-16\*02    −17     9                −6      KDE            NA      NA             NA      NA            Yes     /                                    
  TRB          TRBV20-1\*05    0       7                −3      TRBD2\*01      −5      3              −2      TRBJ2-3\*01   Yes     /                                    
  TRD+         TRDD2\*01       −6      5                NA      NA             NA      NA             0       TRDD3\*01     Yes     /                                    
  TRG          TRGV9\*01       0       5                NA      NA             NA      NA             −1      TRGJP1\*01    Yes     /                                    
  TRG          TRGV3\*02       0       4                NA      NA             NA      NA             0       TRGJ1\*02     Yes     /                                    
  BG_5418      B               IGH     IGHV4-30-2\*01   −14     34             0       IGHD3-3\*01    −7      8             −11     IGHJ6\*02                    Yes     /
  IGH          IGHV3-7\*02     −1      2                −10     IGHD2-2\*01    −5      6              −4      IGHJ6\*02     Yes     /                                    
  IGK          IGKV3-20\*01    −3      3                NA      NA             NA      NA             0       KDE           Yes     /                                    
  IGL          IGLV2-8\*01     −9      8                NA      NA             NA      NA             0       IGLJ2\*01     Yes     /                                    
  TRG          TRGV9\*01       −10     10               NA      NA             NA      NA             −5      TRGJ1\*02     Yes     /                                    
  TRG          TRGV11\*01      −7      8                NA      NA             NA      NA             −3      TRGJ1\*02     Yes     /                                    
  BG_5452      T               IGH     IGHV3-11\*01     0       19             −2      IGHD6-19\*01   −4      4             −9      IGHJ4\*02                    Yes     /
  IGH          IGHV3-64D\*06   −2      33               2       IGHD6-19\*01   −4      4              9       IGHJ4\*02     Yes     /                                    
  IGH          IGHV4-34\*01    0       6                1       IGHD6-6\*01    −7      1              0       IGHJ6\*02     Yes     /                                    
  IGH+         NA              NA      NA               NA      IGHD7-27\*01   −2      3              −3      IGHJ2\*01     Yes     /                                    
  TRB          NA              NA      NA               NA      TRBD1          33      0              0       TRBJ2-3       Yes     /                                    
  TRB          TRBV9\*01       −3      10               NA      TRBD2\*01      NA      NA             0       TRBJ2-1\*01   Yes     /                                    
  TRG          TRGV10\*02      −2      11               NA      NA             NA      NA             −6      TRGJ1\*02     Yes     /                                    
  TRG          TRGV2\*01       0       3                NA      NA             NA      NA             −1      TRGJ1\*02     Yes     /                                    
  BG_9574      T               TRB     TRBV14\*01       −1      11             −4      NA             NA      NA            NA      TRBJ2-7\*01                  Yes     /
  TRB          TRBV5-3\*01     −2      3                0       TRBD1\*01      −3      27             −4      TRBJ2-7\*01   Yes     /                                    
  TRD          TRDV1\*01       −5      5                0       TRDD2\*01      0       11             0       TRDJ1\*01     Yes     /                                    
  TRG          TRGV11\*01      −11     3                −2      NA             NA      NA             NA      TRGJ2\*01     Yes     /                                    
  TRG          TRGV4\*02       −6      2                −1      NA             NA      NA             NA      TRGJ1\*02     Yes     /                                    
  TRG          TRGV8\*01       −1      3                −3      NA             NA      NA             NA      TRGJP2\*01    Yes     /                                    
  BG_9813      T               TRB+    NA               NA      NA             NA      TRBD2\*01      −3      0             −5      TRBJ2-5\*01                  Yes     /
  BG_9813      T               TRD+    TRDD2\*01        −10     22             NA      NA             NA      NA            0       TRDJ1\*01                    Yes     /
  TRG          TRGV10\*02      −1      3                NA      NA             NA      NA             −6      TRGJ1\*02     Yes     /                                    
  TRG          TRGV9\*01       −3      3                NA      NA             NA      NA             0       TRGJ2\*01     Yes     /                                    
  BG_11360     B               IGH     IGHV4-4\*07      −2      9              −1      IGHD2-15\*01   −6      12            −30     IGHJ6\*04                    Yes     /
  IGH+         NA              NA      NA               NA      IGHD7-27\*01   0       12             −7      IGHJ6\*02     Yes     /                                    
  TRD+         TRDD2\*01       0       5                NA      NA             NA      NA             −1      TRDD3\*01     Yes     /                                    
  TRD+         TRDV2\*02       0       13               NA      NA             NA      NA             −3      TRDD3\*01     Yes     /                                    
  BG_11720     B               IGH     IGHV6-1\*01      0       5              −3      IGHD3-3\*01    −2      2             −6      IGHJ6\*02                    Yes     /
  TRA+D        TRDV2\*03       0       5                −2      TRDD3\*01      0       3              −4      TRAJ9\*01     Yes     /                                    
  TRG          TRGV9\*01       −6      13               NA      NA             NA      NA             −1      TRGJ1\*02     Yes     /                                    
  BG_11806     B               IGH     IGHV1-2\*02      −1      3              −3      IGHD2-21\*02   −3      24            −1      IGHJ5\*02                    Yes     /
  IGK          IGKV2-28\*01    0       6                NA      NA             NA      NA             −1      IGKJ4\*02     Yes     /                                    
  IGL          IGLV3-19\*01    −5      14               NA      NA             NA      NA             −4      IGLJ3\*02     Yes     /                                    
  TRD+         TRDD2\*01       0       2                NA      NA             NA      NA             0       TRDD3\*01     Yes     /                                    
  TRG          TRGV5\*01       0       3                NA      NA             NA      NA             −1      TRGJ1\*02     Yes     /                                    
  BG_11806     B               TRD+    TRDD2\*01        0       13             NA      NA             NA      NA            0       TRDJ3\*01                    No      Uncommon V/DJ combinations
  TRA+D        TRDD2\*01       −2      3                NA      NA             NA      NA             −7      TRAJ30\*01    No      Uncommon V/DJ combinations           
  BG_5038      B               TRA+D   TRDD2\*01        −3      53             NA      NA             NA      NA            −15     TRAJ48\*01                   No      Uncommon V/DJ combinations
  BG_5418      B               TRA+D   TRDD2\*01        −1      14             NA      NA             NA      NA            −5      TRAJ29\*01                   No      Uncommon V/DJ combinations
  TRA+D        TRDD2\*01       −11     4                NA      NA             NA      NA             −1      TRAJ23\*01    No      Uncommon V/DJ combinations           
  TRA          TRAV26-1\*01    0       4                NA      NA             NA      NA             −2      TRAJ33\*01    No      Uncommon V/DJ combinations           
  TRA          TRAV8-3\*01     0       8                NA      NA             NA      NA             −7      TRAJ34\*01    No      Uncommon V/DJ combinations           
  BG_5452      T               TRA     TRAV21\*01       0       1              NA      NA             NA      NA            0       TRAJ48\*01                   No      Uncommon V/DJ combinations
  BG_9574      T               TRA+D   TRAV29/DV5\*01   0       38             0       TRDD3\*01      −4      3             0       TRDJ1\*01                    No      Uncommon V/DJ combinations
  TRA          TRAV21\*02      −7      0                −5      NA             NA      NA             NA      TRAJ24\*02    No      Uncommon V/DJ combinations           
  BG_9813      T               TRA     TRAV19\*01       −2      10             NA      NA             NA      NA            −4      TRAJ36\*01                   No      Uncommon V/DJ combinations
  BG_11360     B               IGH     IGHV4-34\*01     0       9              −18     IGHD2-2\*01    0       2             −4      IGHJ6\*03                    No      Oligoclonality
  BG_11720     B               IGH     IGHV4-34\*01     0       6              −1      IGHD6-6\*01    −7      1             0       IGHJ6\*02                    No      Oligoclonality
  BG_371       B               IGK     IGKV1-33\*01     −1      2              NA      NA             NA      NA            −2      IGKJ4\*01                    No      Oligoclonality
  IGK          IGKV1-39\*01    −4      8                NA      NA             NA      NA             −9      IGKJ2\*02     No      Oligoclonality                       
  TRG          TRGV4\*02       −4      5                NA      NA             NA      NA             −3      TRGJ1\*01     No      Oligoclonality                       
  BG_5418      B               TRB     TRBV23-1\*01     0       1              0       TRBD2\*01      −7      14            −6      TRBJ2-7\*01                  No      Oligoclonality
  TRB          TRBV10-3\*01    −8      18               −7      TRBD2\*01      NA      NA             NA      TRBJ2-3\*01   No      Oligoclonality                       
  TRB          TRBV24-1\*01    −13     5                −2      TRBD1\*01      −3      5              2       TRBJ2-7\*01   No      Oligoclonality                       
  BG_5452      T               IGH     IGHV6-1\*01      0       5              −3      IGHD3-3\*01    −2      2             −6      IGHJ6\*02                    No      Oligoclonality
  BG_9574      T               TRG     TRGV11\*01       0       1              −25     NA             NA      NA            NA      TRGJ1\*02                    No      Oligoclonality
  BG_11360     B               IGL     IGLV3-10\*01     −2      7              NA      NA             NA      NA            0       IGLJ3\*02                    No      Low represented clone
  BG_371       B               IGH     IGHV1-3\*02      −2      4              −17     IGHD3-16\*01   −15     0             −18     IGHJ4\*02                    No      Low represented clone
  BG_9813      T               TRB     TRBV4-3\*01      −1      21             −6      TRBD2\*02      NA      NA            NA      TRBJ1-1\*01                  No      Low represented clone

IGK: IGκ rearrangements, IGL: IGλ rearrangements, TRB: TCRβ rearrangements, TRG: TCRγ rearrangements, TRD: TCRδ rearrangements, and TRA: TCRα rearrangements. Symbol "+" refers to incomplete rearrangements. del V: nucleotides deletion in V gene segment, *n*: number of inserted nucleotides, del D: nucleotides deletion in D gene segment, del J: nucleotides deletion in J gene segment, NA: not applicable, Yes: rearrangement already identified by standard procedure, No: rearrangement identified by NGS and not previously identified by standard procedure.

cancers-12-01505-t002_Table 2

###### 

Ig/TCR rearrangements identified by NGS in the minimal residual disease (MRD)-unknown cohort of adult ALL patients enrolled into the NILG-ALL 09/00 clinical trial. These rearrangements have not been previously identified by standard clonality assessment and Sanger sequencing following the conventional EuroMRD guidelines, or they were not adequate to generate a suitable patient-specific molecular probe for the MRD evaluation.

  Patient ID   ALL Lineage     Locus   V Gene         del V   *n*            del D   D Gene         del D   *n*           del J   J Gene              Validation   Rearrangement Feature
  ------------ --------------- ------- -------------- ------- -------------- ------- -------------- ------- ------------- ------- ------------------- ------------ -----------------------
  BG_11584     B               IGH     IGHV6-1\*01    −2      8              −6      IGHD6-6\*01    0       3             −10     IGHJ4\*02           Yes          /
  BG_2097      B               IGH     NA             NA      NA             NA      IGHD4-23\*01   −2      1             −4      IGHJ2\*01           Yes          /
  BG_855       B               IGH     IGHV6-1\*01    −3      2              −4      IGHD2-2\*01    −1      5             0       IGHJ6\*03           Yes          /
  IGH          IGHV3-23\*01    0       19             −2      IGHD3-9\*01    −8      13             −7      IGHJ4\*02     Yes     /                                
  BG_10112     B               IGH+    NA             NA      NA             NA      IGHD6-6\*01    −2      0             −7      IGHJ4\*02           Yes          /
  IGH+         NA              NA      NA             NA      IGHD1-7\*01    −6      2              −4      IGHJ4\*02     Yes     /                                
  BG_11053     B               IGH+    NA             NA      NA             NA      IGHD2-2\*01    −6      3             −4      IGHJ4\*02           Yes          /
  BG_1125      B               IGH+    NA             NA      NA             NA      IGHD6-25\*01   0       −5            11      IGHJ4\*02           Yes          /
  BG_11584     B               IGH+    NA             NA      NA             NA      IGHD1-26\*01   0       3             −3      IGHJ3\*02           Yes          /
  BG_4254      B               IGH+    NA             NA      NA             NA      IGHD3-9\*01    −5      4             −11     IGHJ6\*03           Yes          /
  IGH+         NA              NA      NA             NA      IGHD6-6\*01    −4      3              −15     IGHJ5\*02     Yes     /                                
  BG_5702      B               IGH+    NA             NA      NA             NA      IGHD2-2\*02    −6      7             −5      IGHJ5\*02           Yes          /
  BG_8345      B               IGH+    NA             NA      NA             NA      IGHD3-22\*01   −2      7             1       IGHJ6\*02           Yes          /
  IGH+         NA              NA      NA             NA      IGHD1-26\*01   −2      0              7       IGHJ4\*02     Yes     /                                
  BG_9445      B               IGH+    NA             NA      NA             NA      IGHD2-2\*02    −3      19            5       IGHJ6\*03           Yes          /
  BG_11269     T               TRB     TRBV7-8\*01    −3      14             NA      NA             NA      NA            −7      TRBJ1-4\*01         Yes          /
  BG_6037      T               TRB     TRBV4-2\*01    0       25             NA      NA             NA      NA            −3      TRBJ2-3\*01         Yes          /
  TRB          TRBV20-1\*02    −3      15             −2      TRBD2\*02      −2      19             −6      TRBJ2-1\*01   Yes     /                                
  BG_10112     B               TRG     TRGV11\*01     −4      7              NA      NA             NA      NA            −8      TRGJP1\*01          Yes          /
  TRG          TRGV11\*01      −3      10             NA      NA             NA      NA             −1      TRGJ2\*01     Yes     /                                
  BG_11269     T               TRG     TRGV4\*02      −4      5              NA      NA             NA      NA            0       TRGJ2\*01           Yes          /
  TRG          TRGV10\*02      −6      0              NA      NA             NA      NA             −8      TRGJ1\*02     Yes     /                                
  BG_11584     B               TRG     TRGV4\*02      −6      2              NA      NA             NA      NA            0       TRGJ2\*01           Yes          /
  TRG          TRGV10\*02      0       NA             NA      NA             NA      4              −9      TRGJP1\*01    Yes     /                                
  TRG          TRGV11\*01      0       0              NA      NA             NA      NA             −7      TRGJP1\*01    Yes     /                                
  BG_855       B               TRG     TRGV9\*01      −10     3              NA      NA             NA      NA            −2      TRGJ1\*02           Yes          /
  BG_11053     B               TRD+    NA             NA      NA             NA      TRDD2\*01      −1      22            −1      TRDJ1\*01           Yes          /
  TRD+         NA              NA      NA             NA      TRDD2\*01      0       19             0       TRDJ4\*01     Yes     /                                
  BG_4254      B               TRD+    NA             NA      NA             NA      TRDD2\*01      0       5             −2      TRDD3\*01           Yes          /
  BG_8345      B               TRD+    NA             NA      NA             NA      TRDD2\*01      −3      15            0       TRDD3\*01           Yes          /
  BG_11053     B               IGH+    NA             NA      NA             NA      IGHD3-9\*01    −5      3             −4      IGHJ4\*02           Yes          Oligoclonality
  IGH+         NA              NA      NA             NA      IGHD3-9\*01    −5      0              −4      IGHJ6\*02     Yes     Oligoclonality                   
  IGH+         NA              NA      NA             NA      IGHD3-9\*01    −3      13             −6      IGHJ6\*02     Yes     Oligoclonality                   
  BG_11345     T               TRD+    NA             NA      NA             NA      TRDD2\*01      −8      0             −14     TRDD3\*01           Yes          Oligoclonality
  BG_1125      B               IGK     IGKV1-27\*01   −1      0              NA      NA             NA      NA            2       IGKJ1\*01           YesŦ         /
  BG_11269     T               IGK     IGKV4-1\*01    −1      0              NA      NA             NA      NA            −4      IGKJ4\*01           YesŦ         /
  IGK          IGKV2D-29\*01   −2      6              NA      NA             NA      NA             0       IGKJ2\*01     YesŦ    /                                
  IGK          IGKV1-6\*01     −3      0              NA      NA             NA      NA             0       IGKJ1\*01     YesŦ    /                                
  BG_6037      T               TRG     TRGV3\*01      0       0              NA      NA             NA      NA            0       TRGJ1\*02           YesŦ         /
  TRG          TRGV2\*01       0       4              NA      NA             NA      NA             −2      TRGJ1\*02     YesŦ    /                                
  BG_2097      B               TRA+D   TRDV1\*01      −2      8              NA      NA             NA      NA            −8      TRAJ29\*01          YesŦ         /
  BG_855       B               TRA+D   NA             NA      NA             NA      TRDD2\*01      −4      24            −5      TRAJ29\*01          YesŦ         /
  TRA+D        TRDV2\*01       0       6              0       TRDD3\*01      0       5              −4      TRAJ58\*01    YesŦ    /                                
  BG_11269     T               TRA     TRAV26-1\*01   −3      3              NA      NA             NA      NA            −4      TRAJ4\*01           YesŦ         /
  BG_12438     T               TRA     TRAV19\*01     −8      4              NA      NA             NA      NA            0       TRAJ47\*02          YesŦ         /
  BG_2097      B               TRA     TRAV13-1\*01   −3      0              NA      NA             NA      NA            −3      TRAJ35\*01          YesŦ         /
  BG_5702      B               TRA     TRAV16\*01     −6      2              NA      NA             NA      NA            −4      TRAJ9\*01           YesŦ         /
  BG_10487     B               IGH+    NA             NA      NA             NA      IGHD3-16\*02   −5      8             0       IGHJ4\*02           YesŦ         Biclonal sequence
  IGH+         NA              NA      NA             NA      IGHD3-3\*01    0       11             −3      IGHJ5\*02     YesŦ    Biclonal sequence                
  BG_6490      B               IGH+    NA             NA      NA             NA      IGHD2-21\*02   −1      2             0       IGHJ6\*03           YesŦ         Biclonal sequence
  IGH+         NA              NA      NA             NA      IGHD2-8\*01    −7      8              −2      IGHJ3\*02     YesŦ    Biclonal sequence                
  BG_8646      T               TRD+    NA             NA      NA             NA      TRDD2\*01      −8      0             −14     TRDD3\*01           YesŦ         Biclonal sequence
  TRD+         NA              NA      NA             NA      TRDD2\*01      −8      0              −16     TRDD3\*01     YesŦ    Biclonal sequence                
  BG_1125      B               IGH     IGHV4-34\*02   0       10             NA      NA             NA      NA            −4      IGHJ5\*01           No           Low represented clone
  BG_5702      B               IGK     IGKV2-28\*01   −3      2              −7      KDE            NA      NA            NA      NA                  No           Low represented clone
  BG_12438     T               TRB     TRBV4-1\*02    −3      2              −1      TRBD1\*01      −3      8             −2      TRBJ2-7\*01         No           Low represented clone
  BG_5702      B               TRB     TRBV4-1\*02    0       2              0       TRBD1\*01      −4      10            −8      TRBJ1-1\*01         No           Low represented clone
  BG_11053     B               TRG     TRGV9\*01      −1      6              NA      NA             NA      NA            0       TRGJ1\*02           No           Low represented clone
  BG_3895      T               TRG     TRGV2\*01      0       4              NA      NA             NA      NA            −10     TRGJP2\*01          No           Low represented clone
  BG_11053     B               TRD+    NA             NA      NA             NA      TRDD2\*01      0       14            −10     TRDJ1\*01           No           Low represented clone
  BG_12438     T               TRA     TRAV21\*01     −4      7              NA      NA             NA      NA            0       TRAJ27\*01          No           Low represented clone
  BG_2097      B               TRA     TRAV19\*01     −10     5              NA      NA             NA      NA            0       TRAJ47\*01          No           Low represented clone
  BG_6490      B               IGH     IGHV4-34\*12   0       9              1       IGHD2-8\*02    −7      8             −2      IGHJ3\*02           No           Oligoclonality
  BG_5702      B               IGK     IGKV3-20\*01   −4      6              NA      NA             NA      NA            −2      IGKJ2\*01           No           Oligoclonality
  BG_2097      B               TRB     TRBV6-5\*01    0       2              −4      TRBD2\*01      −7      0             −4      TRBJ1-5\*01         No           Oligoclonality
  BG_11053     B               TRG     TRGV4\*02      −3      0              NA      NA             NA      NA            −4      TRGJ2\*01           No           Oligoclonality
  TRG          TRGV11\*01      −7      7              NA      NA             NA      NA             −1      TRGJ2\*01     No      Oligoclonality                   
  BG_2097      B               TRG     TRGV3\*01      0       15             NA      NA             NA      NA            −1      TRGJ2\*01           No           Oligoclonality
  BG_9445      B               TRG     TRGV10\*02     0       3              NA      NA             NA      NA            4       TRGJ1\*01           No           Oligoclonality
  BG_11584     B               IGH     IGHV4-31\*02   −1      1              −3      IGHD3-10\*01   −6      0             0       IGHJ4\*02           ND           \<5%
  BG_2481      T               IGH     NA             NA      NA             NA      IGHD7-27\*01   −11     0             0       IGHJ1\*01           ND           \<5%
  BG_11054     B               IGH+    NA             NA      NA             NA      IGHD6-13\*01   3       0             21      IGHJ1\*01           ND           \<5%
  IGH+         NA              NA      NA             NA      IGHD7-27\*01   0       2              6       IGHJ4\*02     ND      \<5%                             
  BG_10112     B               TRG     TRGV5\*01      0       6              NA      NA             NA      NA            −1      TRGJ1\*02           ND           \<5%
  TRG          TRGV9\*01       0       9              NA      NA             NA      NA             0       TRGJ1\*02     ND      \<5%                             
  TRG          TRGV11\*01      −9      12             NA      NA             NA      NA             −5      TRGJ1\*02     ND      \<5%                             
  TRG          TRGV9\*01       −2      4              NA      NA             NA      NA             0       TRGJ2\*01     ND      \<5%                             
  TRG          TRGV9\*01       0       4              NA      NA             NA      NA             −2      TRGJ2\*01     ND      \<5%                             
  BG_11053     B               TRG     TRGV10\*02     −2      0              NA      NA             NA      NA            −1      TRGJ2\*01           ND           \<5%
  TRG          TRGV11\*01      −2      15             NA      NA             NA      NA             0       TRGJ1\*02     ND      \<5%                             
  TRG          TRGV11\*01      0       10             NA      NA             NA      NA             −8      TRGJ1\*01     ND      \<5%                             
  TRG          TRGV5\*01       0       3              NA      NA             NA      NA             −5      TRGJ1\*02     ND      \<5%                             
  BG_11584     B               TRG     TRGV11\*01     0       NA             NA      NA             NA      5             −2      TRGJ1\*02           ND           \<5%
  TRG          TRGV11\*01      −7      NA             NA      NA             NA      3              −7      TRGJP1\*01    ND      \<5%                             
  TRG          TRGV9\*01       −2      NA             NA      NA             NA      11             −8      TRGJ1\*01     ND      \<5%                             
  TRG          TRGV11\*01      −3      NA             NA      NA             NA      0              −16     TRGJ1\*02     ND      \<5%                             
  BG_2097      B               TRG     TRGV4\*02      0       6              NA      NA             NA      NA            −5      TRGJP1\*01          ND           \<5%
  TRG          TRGV4\*01       −5      14             NA      NA             NA      NA             0       TRGJ1\*02     ND      \<5%                             
  BG_11053     B               TRD+    NA             NA      NA             NA      TRDD2\*01      0       16            0       TRDJ1\*01           ND           \<5%
  BG_12438     T               TRG     TRGV8\*01      1       0              NA      NA             NA      NA            −7      TRGJP2\*01          ND           ND
  BG_10640     B               IGH+    NA             NA      NA             NA      IGHD3-3\*01    −4      6             −5      IGHJ6\*02           ND•          ND
  IGH+         NA              NA      NA             NA      IGHD2-2\*02    −3      4              −10     IGHJ6\*02     ND•     ND                               
  BG_4005      T               Na      Na             Na      Na             Na      Na             Na      Na            Na      Na                  ND           /
  BG_4255      T               Na      Na             Na      Na             Na      Na             Na      Na            Na      Na                  ND           /
  BG_4379      T               Na      Na             Na      Na             Na      Na             Na      Na            Na      Na                  ND           /

For patients BG_4005, BG_4255, and BG_4379, we detected no Ig/TCR rearrangements. IGK: IGκ rearrangements, IGL: IGλ rearrangements, TRB: TCRβ rearrangements, TRG: TCRγ rearrangements, TRD: TCRδ rearrangements, and TRA: TCRα rearrangements. Symbol "+" refers to incomplete rearrangements. del V: nucleotides deletion in V gene segment, *n*: number of inserted nucleotides, del D: nucleotides deletion in D gene segment, del J: nucleotides deletion in J gene segment, NA: not applicable, Na: not available, Yes: rearrangement confirmed by standard procedure, Ŧ: use of specific primers for conventional PCR set-up required, No: rearrangement identified by NGS not validated by standard procedure, ND: not done, ND•: not done/exhausted diagnostic material.
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###### 

Ig/TCR rearrangements identified by NGS in the MRD-unknown cohort of newly diagnosed adult ALL patients. These rearrangements have not been previously identified by standard clonality assessment and Sanger sequencing following the conventional EuroMRD guidelines, or they were not adequate to generate a suitable patient-specific molecular probe for the MRD evaluation.

  Patient ID   ALL lineage    Locus   V Gene           del V   *n*           del D   D Gene              del D   *n*          del J   J Gene                                                 Known   Rearrangement feature
  ------------ -------------- ------- ---------------- ------- ------------- ------- ------------------- ------- ------------ ------- ------------------------------------------------------ ------- ------------------------------------------------------
  BG_41182     B              TRG     TRGV9\*01        −1      0             NA      NA                  NA      NA           −8      TRGJ1\*02                                              Yes     /
  TRG          TRGV9\*01      −2      3                NA      NA            NA      NA                  0       TRGJ2\*01    Yes     /                                                              
  BG_41408     T              TRB     TRBV6-1\*01      −10     26            NA      NA                  NA      NA           0       TRBJ2-1\*01                                            Yes     /
  TRG          TRGV11\*01     −2      8                NA      NA            NA      NA                  0       TRGJP2\*01   Yes     /                                                              
  TRG          TRGV2\*01      −25     0                NA      NA            NA      NA                  0       TRGJP2\*01   Yes     /                                                              
  TRD          TRDV2\*02      −4      31               NA      NA            NA      NA                  0       TRDJ1\*01    Yes     /                                                              
  BG_41985     B              TRG     TRGV2\*02        −4      5             NA      NA                  NA      NA           −7      TRGJ1\*02                                              Yes     /
  TRG          TRGV3\*01      −1      5                NA      NA            NA      NA                  0       TRGJP2\*01   Yes     /                                                              
  TRG          TRGV10\*02     −1      6                NA      NA            NA      NA                  −8      TRGJ1\*02    Yes     /                                                              
  BG_42228     T              TRB+    NA               NA      NA            NA      TRBD2\*01           −2      1            −5      TRBJ2-7\*01                                            Yes     /
  TRG          TRGV2\*02      0       4                NA      NA            NA      NA                  −2      TRGJ1\*02    Yes     /                                                              
  TRG          TRGV2\*01      0       6                NA      NA            NA      NA                  −9      TRGJ1\*02    Yes     /                                                              
  BG_42309     B              IGH     IGHV3-23\*01     −4      19            −9      IGHD3/OR15-3a\*01   −9      8            −11     IGHJ6\*02                                              Yes     /
  IGK+         Intron         0       2                NA      NA            NA      NA                  −5      KDE          Yes     /                                                              
  BG_41985     B              IGH+    NA               NA      NA            NA      IGHD1-7\*01         0       1            −2      IGHJ6\*02                                              ND•     /
  IGH+         NA             NA      NA               NA      IGHD1-7\*01   −3      11                  −17     IGHJ6\*02    ND•     /                                                              
  BG_41165     T              TRB     TRBV30\*02       −2      10            NA      NA                  NA      NA           0       TRBJ1-4\*01                                            Na      Uncommon V/DJ combinations and low represented clone
  TRA          TRAV19\*01     −2      4                NA      NA            NA      NA                  −3      TRAJ50\*01   Na      Uncommon V/DJ combinations and low represented clone           
  BG_41408     T              TRD     TRDV1\*01        −8      20            0       TRDD3\*01           −3      5            −3      TRDJ4\*01                                              Na      Uncommon V/DJ combinations
  BG_42228     T              TRD     TRDV3\*01        −1      9             0       TRDD3\*01           −1      0            −3      TRDJ1\*01                                              Na      Uncommon V/DJ combinations
  TRA          TRAV21\*01     −4      1                NA      NA            NA      NA                  −1      TRAJ29\*01   Na      Uncommon V/DJ combinations                                     
  BG_42309     B              IGK     GKV3-15\*01      0       3             NA      NA                  NA      NA           −1      IGKJ2\*03                                              Na      Uncommon V/DJ combinations
  IGL          IGLV2-23\*01   0       1                NA      NA            NA      NA                  0       IGLJ3\*02    Na      Uncommon V/DJ combinations                                     
  BG_37265     T-LL           IGK+    IGKV3-15\*01     −2      5             NA      NA                  NA      NA           6       KDE                                                    Na      Uncommon and NT in T-lineage
  IGK+         IGKV2-28\*01   −3      0                NA      NA            NA      NA                  0       IGKJ4\*01    Na      Uncommon and NT in T-lineage                                   
  IGK+         IGKV1-33\*01   −3      0                NA      NA            NA      NA                  0       IGKJ4\*01    Na      Uncommon and NT in T-lineage                                   
  BG_41182     B              TRA+D   NA               NA      NA            NA      TRDD2\*01           −3      7            −3      TRAJ48\*01                                             No-Na   Uncommon V/DJ combinations
  IGL          IGLV4-3\*01    0       2                NA      NA            NA      NA                  −2      IGLJ3\*02    No      Uncommon V/DJ combinations                                     
  IGL          IGLV3-1\*01    −4      3                NA      NA            NA      NA                  −5      IGLJ2\*01    No      Uncommon V/DJ combinations                                     
  TRG          TRGV10\*02     −19     8                NA      NA            NA      NA                  −17     TRGJP1\*01   No      Uncommon V/DJ combinations                                     
  BG_41408     T              TRB     TRBV9\*01        −4      15            NA      NA                  NA      NA           0       TRBJ2-1\*01                                            No      Oligoclonality
  BG_40129     T              TRD+    TRDV2\*01        0       2             NA      NA                  NA      NA           0       TRDD3\*01                                              No      Missed by heteroduplex
  BG_41182     B              IGH     IGHV3-38-3\*01   11      9             NA      NA                  NA      NA           2       IGHJ6\*03                                              No      Missed by heteroduplex
  BG_41209     T              TRD+    NA               NA      NA            NA      TRDD2\*01           −7      4            −13     TRDD3\*01                                              No      Missed by heteroduplex
  BG_42228     T              TRB     TRBV4-1\*02      0       4             0       TRBD2\*01           −2      0            −5      TRBJ2-1\*01                                            No      Missed by heteroduplex
  BG_42309     B              IGK+    IGKV1-17\*01     −1      0             NA      NA                  NA      NA           8       KDE                                                    No      Missed by heteroduplex
  BG_39652     T-LL           TRG     TRGV4\*01        −2      0             NA      NA                  NA      NA           −5      TRGJ1\*01                                              No      Low represented clone
  BG_41165     T              TRG     TRGV4\*01        0       4             NA      NA                  NA      NA           −11     TRGJ1\*02                                              No      Low represented clone
  TRG          TRGV11\*01     −11     17               NA      NA            NA      NA                  6       TRGJP\*01    No      Low represented clone                                          
  BG_41182     B              TRG     TRGV2\*01        −3      2             NA      NA                  NA      NA           −8      TRGJ1\*02                                              No      Low represented clone
  BG_41733     T              Na      Na               Na      Na            Na      Na                  Na      Na           Na      Na                                                     ND      /
  BG_9541      T              Na      Na               Na      Na            Na      Na                  Na      Na           Na      Na                                                     ND      /

For patients BG_41733 and BG_9541, no Ig/TCR rearrangements were detected. T-LL: T-lymphoblastic lymphoma, IGK: IGκ rearrangements, IGL: IGλ rearrangements, TRB: TCRβ rearrangements, TRG: TCRγ rearrangements, TRD: TCRδ rearrangements, and TRA: TCRα rearrangements. Symbol "+" refers to incomplete rearrangements. del V: nucleotides deletion in V gene segment, *n*: number of inserted nucleotides, del D: nucleotides deletion in D gene segment, del J: nucleotides deletion in J gene segment, NA: not applicable, Na: not available, Yes: rearrangement already identified by standard procedure, No: rearrangement identified by NGS and not previously identified by standard procedure, ND: not done, ND•: not done/exhausted diagnostic material.
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###### 

List of gene variants identified in 18 out of 19 adult ALL patients of which 7 were formerly evaluated for Ig/TCR rearrangements and 12 were newly-diagnosed ALL patients.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient ID   Gene       HGVSc                                                           HGVSp                                    VAF    RD     ARD    Consequence
  ------------ ---------- --------------------------------------------------------------- ---------------------------------------- ------ ------ ------ --------------------------------
  BG_42309     *CREBBP*   NM_004380.2:c.4427C\>T                                          NP_004371.2:p.Pro1476Leu                 78.6   641    504    missense_variant

  BG_40129     *EZH2*     NM_004456.4:c.1613C\>T                                          NP_004447.2:p.Ser538Leu                  51.7   410    212    missense_variant

  BG_40129     *EZH2*     NM_004456.4:c.347T\>C                                           NP_004447.2:p.Leu116Pro                  43.3   282    122    missense_variant

  BG_41733     *EZH2*     NM_004456.4:c.1987T\>A                                          NP_004447.2:p.Tyr663Asn                  18.2   292    53     missense_variant

  BG_40129     *FBXW7*    NM_033632.3:c.1513C\>T                                          NP_361014.1:p.Arg505Cys                  7.4    542    40     missense_variant

  BG_4379      *FBXW7*    NM_033632.3:c.62G\>A                                            NP_361014.1:p.Gly21Asp                   47.7   2514   1200   missense_variant

  BG_41165     *FLT3*     NM_004119.2:c.1779_1793dupTTTCAGAGAATATGA                       NP_004110.2:p.Asp593_Tyr597dup           11.8   330    39     inframe_insertion

  BG_41985     *FLT3*     NM_004119.2:c.2503G\>A                                          NP_004110.2:p.Asp835Asn                  27.6   181    50     missense_variant

  BG_4379      *FLT3*     NM_004119.2:c.2864A\>G                                          NP_004110.2:p.Tyr955Cys                  51.7   1412   730    missense_variant

  BG_37265     *IDH2*     NM_002168.2:c.419G\>A                                           NP_002159.2:p.Arg140Gln                  22.7   1122   255    missense_variant

  BG_39652     *IDH2*     NM_002168.2:c.547delGACinsAAG                                   NP_002159.2:p.Asp183Lys                  5.6    144    8      missense_variant

  BG_41733     *IDH2*     NM_002168.2:c.419G\>A                                           NP_002159.2:p.Arg140Gln                  45.8   690    316    missense_variant

  BG_4379      *IDH2*     NM_002168.2:c.419G\>A                                           NP_002159.2:p.Arg140Gln                  42.9   1559   668    missense_variant

  BG_41165     *IKZF1*    NM_006060.4_dupl12.1:c.849G\>T                                  NP_006051.1_dupl12.1:p.Arg284Leu         43.6   165    72     missense_variant

  BG_4379      *IKZF1*    NM_006060.4_dupl12.1:c.396G\>T                                  NP_006051.1_dupl12.1:p.Gly133Val         49.0   514    252    missense_variant

  BG_40129     *JAK1*     NM_002227.2:c.1954T\>C                                          NP_002218.2:p.Tyr652His                  52.5   179    94     missense_variant

  BG_42228     *JAK1*     NM_002227.2:c.2107A\>T                                          NP_002218.2:p.Ser703Cys                  42.8   566    242    missense_variant

  BG_4255      *JAK1*     NM_002227.2:c.2170C\>T                                          NP_002218.2:p.Arg724Cys                  12.2   1199   146    missense_variant

  BG_41182     *JAK2*     NM_004972.3:c.2171T\>C                                          NP_004963.1:p.Ile724Thr                  12.0   465    56     missense_variant

  BG_11269     *JAK3*     NM_000215.3:c.1370G\>A                                          NP_000206.2:p.Cys457Tyr                  49.2   177    87     missense_variant

  BG_40129     *JAK3*     NM_000215.3:c.2570T\>C                                          NP_000206.2:p.Leu857Pro                  47.2   301    142    missense_variant

  BG_40129     *JAK3*     NM_000215.3:c.2536G\>A                                          NP_000206.2:p.Asp846Asn                  13.4   307    41     missense_variant

  BG_42228     *JAK3*     NM_000215.3:c.1533G\>A                                          NP_000206.2:p.Met511Ile                  44.0   650    286    missense_variant

  BG_4255      *JAK3*     NM_000215.3:c.1533G\>A                                          NP_000206.2:p.Met511Ile                  29.1   955    278    missense_variant

  BG_11269     *KRAS*     NM_033360.2:c.182A\>T                                           NP_203524.1:p.Gln61Leu                   6.6    802    53     missense_variant

  BG_10442     *NOTCH1*   NM_017617.3:c.7324_7325insTC                                    NP_060087.3:p.Asp2442ValfsTer36          31.3   412    129    frameshift_variant

  BG_37265     *NOTCH1*   NM_017617.3:c.5033T\>C                                          NP_060087.3:p.Leu1678Pro                 5.8    291    17     missense_variant

  BG_40129     *NOTCH1*   NM_017617.3:c.4799T\>A                                          NP_060087.3:p.Leu1600Gln                 43.8   105    46     missense_variant

  BG_40129     *NOTCH1*   NM_017617.3:c.7541C\>A                                          NP_060087.3:p.Pro2514His                 28.6   276    79     missense_variant

  BG_40129     *NOTCH1*   NM_017617.3:c.7387delG                                          NP_060087.3:p.Ala2463ProfsTer14          5.8    223    13     frameshift_variant

  BG_41209     *NOTCH1*   NM_017617.3:c.5165A\>C                                          NP_060087.3:p.Gln1722Pro                 24.7   174    43     missense_variant,\
                                                                                                                                                        splice_region_variant

  BG_41209     *NOTCH1*   NM_017617.3:c.4787T\>C                                          NP_060087.3:p.Leu1596Pro                 6.0    117    7      missense_variant

  BG_41408     *NOTCH1*   NM_017617.3:c.3394C\>T                                          NP_060087.3:p.Arg1132Cys                 20.6   194    40     missense_variant

  BG_42228     *NOTCH1*   NM_017617.3:c.4778T\>C                                          NP_060087.3:p.Leu1593Pro                 48.7   189    92     missense_variant

  BG_4255      *NOTCH1*   NM_017617.3:c.4776_4777insAGAACC                                NP_060087.3:p.Phe1592_Leu1593insArgThr   19.6   168    33     inframe_insertion

  BG_4255      *NOTCH1*   NM_017617.3:c.141-4A\>G                                                                                  5.2    155    8      splice_region_variant,\
                                                                                                                                                        intron_variant

  BG_37265     *NRAS*     NM_002524.4:c.37G\>C                                            NP_002515.1:p.Gly13Arg                   19.3   1464   283    missense_variant

  BG_41408     *NRAS*     NM_002524.4:c.35G\>A                                            NP_002515.1:p.Gly12Asp                   26.8   1131   303    missense_variant

  BG_4379      *NRAS*     NM_002524.4:c.35G\>A                                            NP_002515.1:p.Gly12Asp                   43.4   2130   924    missense_variant

  BG_5038      *PAX5*     NM_016734.2:c.780+5G\>T                                                                                  45.5   321    146    splice_region_variant,\
                                                                                                                                                        intron_variant

  BG_21292     *PTEN*     NM_000314.4:c.493G\>T                                           NP_000305.3:p.Gly165Ter                  32.9   347    114    stop_gained,\
                                                                                                                                                        splice_region_variant

  BG_21292     *PTEN*     NM_000314.4:c.736_737insAG                                      NP_000305.3:p.Pro246GlnfsTer11           34.3   1130   388    frameshift_variant

  BG_37265     *SH2B3*    NM_005475.2:c.1345G\>A                                          NP_005466.1:p.Glu449Lys                  5.8    924    54     missense_variant

  BG_39652     *SH2B3*    NM_005475.2:c.927-2delAGinsCT                                                                            5.4    112    6      splice_acceptor_variant

  BG_4255      *SH2B3*    NM_005475.2:c.1038dupG                                          NP_005466.1:p.Leu347AlafsTer38           50.2   944    474    frameshift_variant

  BG_39652     *TET2*     NM_001127208.2:c.1588delCAinsTG                                 NP_001120680.1:p.Gln530Trp               6.2    242    15     stop_gained

  BG_41165     *TET2*     NM_001127208.2:c.5733delA                                       NP_001120680.1:p.Lys1911AsnfsTer39       35.7   493    176    frameshift_variant

  BG_10442     *TP53*     NM_000546.5:c.684_685insGGGGTTTGACC                             NP_000537.3:p.Cys229GlyfsTer3            5.9    236    14     stop_gained,frameshift_variant

  BG_10442     *TP53*     NM_000546.5:c.651_654dupGGTG                                    NP_000537.3:p.Pro219GlyfsTer4            33.7   943    318    frameshift_variant

  BG_11584     *TP53*     NM_000546.5:c.844C\>G                                           NP_000537.3:p.Arg282Gly                  4.6    1034   47     missense_variant

  BG_41209     *TP53*     NM_000546.5:c.390_426delCAACAAGATGTTTTGCCAACTGGCCAAGACCTGCCCT   NP_000537.3:p.Asn131CysfsTer27           35.0   117    41     frameshift_variant
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

VAF: variant allele fraction; RD: read depth; ARD: alteration read depth.

[^1]: These authors contributed equally to this work.
